Lateral Pelvic Lymph Node Dissection for rectal cancer – unfinished business?

Benjamin Cribb^{*‡} MBCHB, FRACS

Joseph Kong^{*} PhD, FRACS

Jacob McCormick^{*‡} MBBS, FRACS

Satish Warriar^{*‡} MBBS, FRACS

Professor Alexander Heriot^{*‡†} MD, FRACS

Affiliations:

^{*}Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

[‡]Epworth Healthcare, Melbourne, Victoria, Australia

[†]The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia

The corresponding author is not a recipient of a research scholarship and the paper is not based on a previous communication to a society or meeting.

Author for Correspondence:

Benjamin Cribb
Epworth Healthcare (Medical services JMW)
89 Bridge Road

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1111/ans.15761](https://doi.org/10.1111/ans.15761)

Richmond, VIC 3121
Phone: +613 9426 8967
Fax: +613 9914 8760
Email: benicribb@hotmail.com

Word Count: 1164

Anatomy remains the cornerstone of surgical oncology, with removal of the tumour and its primary draining lymph node basins being a fundamental principle. The advent of refinements such as sentinel node biopsy to aid selection of which patients require radical nodal dissection has gained traction in many fields of surgical oncology such as breast cancer. However, there remains uncertainty as to which nodes require resection for the management of rectal cancer and in particular whether resection of lateral pelvic sidewall lymph nodes is required.

The primary lymphatic drainage of the rectum follows the principle of lymphatics following the arterial supply, and hence is to the mesorectum, and along the route of the inferior mesenteric artery. There is also however a proportion of drainage to the lateral pelvic sidewall lymph nodes which increases as one moves down the rectum¹. The majority of these findings were derived from work in Japan and this strongly influenced the management policy for low rectal cancer in Japan, with lateral pelvic lymph node dissection (LPLND), in conjunction with total mesorectal excision (TME), considered standard of care for extraperitoneal rectal cancers. The Japanese guidelines highlighted that in locally advanced low rectal cancers, up to 30% had involved lateral pelvic sidewall lymph nodes, sometimes in the absence of mesorectal nodal involvement². This 'Eastern' approach is in sharp contrast to the 'Western' approach to locally advanced rectal cancer which utilizes neoadjuvant chemoradiotherapy prior to surgical

resection with TME, with the assumption that neoadjuvant therapy will sterilize any nodal metastasis present outside the mesorectum, thus negating the requirement for LPLND³.

The debate between the two approaches has been present for decades⁴, however there is now the realisation that neither individual approach completely addresses the problem of lateral pelvic recurrence, with lateral recurrence gaining more prevalence as overall rectal cancer treatment improves^{5,6}.

The concept of selective application of both neoadjuvant therapy and LPLND has been raised in both the East and the West with the utilization of both modalities resulting in a reduction⁷⁻⁹, or even elimination¹⁰, of lateral recurrences. LPLND however does result in increased morbidity with increased blood loss and longer operating time, even in the hands of experienced surgeons, as demonstrated by a Japanese randomized controlled trial of LPLND¹¹. This may be a greater issue in western patients with a generally higher body mass index. Therefore, when considering the potential benefit for some patients though at the expense of increased morbidity, the selection of patients for LPLND becomes a very important factor. The majority of the discussion has focused on the preoperative identification of lymph node involvement, with nodal size and appearance being the main assessment criteria on imaging, with the size ranging from >10mm¹¹, down to 7mm⁹. The concept that neoadjuvant therapy will sterilize a significant proportion of pelvic side wall lymph nodes¹², means that it may be the lymph node size post neoadjuvant therapy that is most important. Oguru et al reported that whilst pretherapy lymph node size of 7 mm was significant, post neoadjuvant therapy 4mm

should be the criteria for persistent involvement¹³, with another study reporting 5 mm¹⁰. However, restaging following neoadjuvant therapy is not routinely undertaken across Australasia, and in Australia rectal cancer restaging with an MRI scan is not covered by Medicare.

With increasing evidence and interest in LPLND, patient selection and surgeon experience remain challenges in Australasia. A recent survey on lateral pelvic lymph nodes in rectal cancer across members of the Colorectal Surgical Society of Australia and New Zealand (CSSANZ) identified a number of issues. Neoadjuvant chemoradiotherapy was recommended by 92% of respondents for involved lateral pelvic nodes and 86% recommended LPLND for persistent nodal involvement. Almost 60% of surgeons however, had received no exposure to lateral pelvic lymph node dissection during their training, and only 21% reported undertaking more than 1 to 2 LPLND per year, with only 4% undertaking more than 10 LPLNDs per year.

Management of lateral pelvic lymph nodes in rectal cancer is likely to remain an area of controversy in rectal cancer management with more evidence required to determine who will benefit from LPLND and to what degree.

References

1. Watanabe T, Muro K, Ajioka Y, et al. Japanese Society for Cancer of the Colon and

- Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. *Int J Clin Oncol*. 2018; 23: 1-34.
2. Ogura A, Akiyoshi T, Nagasaki T, et al. Feasibility of Laparoscopic Total Mesorectal Excision with Extended Lateral Pelvic Lymph Node Dissection for Advanced Lower Rectal Cancer after Preoperative Chemoradiotherapy. *World J Surg*. 2017; 41: 868-75.
  3. Yano H, Moran BJ. The incidence of lateral pelvic side-wall nodal involvement in low rectal cancer may be similar in Japan and the West. *Br J Surg*. 2008; 95: 33–49.
  4. Malakorn S, Chang GJ. Treatment of rectal cancer in the East and West: should it be different? *Surgery*. 2017; 162: 315–6.
  5. Kusters M, van de Velde CJ, Beets-Tan RG, et al. Patterns of local recurrence in rectal cancer: a single-center experience. *Ann Surg Oncol*. 2009; 16: 289–96.
  6. N Beppu N, Kimura F, Aihara T, et al. Patterns of local recurrence and oncologic outcomes in T3 low rectal cancer (≤ 5 cm from the anal verge) treated with short-course radiotherapy with delayed surgery: outcomes in T3 low rectal cancer treated with short-course radiotherapy with delayed surgery. *Ann Surg Oncol*. 2017; 24: 219–26.
  7. Akiyoshi T, Ueno M, Matsueda K, et al. Selective lateral pelvic lymph node dissection in patients with advanced low rectal cancer treated with preoperative chemoradiotherapy based on pretreatment imaging. *Ann Surg Oncol*. 2014; 21: 189–96.
  8. Ishihara S, Kawai K, Tanaka T, et al. Oncological outcomes of lateral pelvic lymph node metastasis in rectal cancer treated with preoperative chemoradiotherapy. *Dis Colon Rectum*. 2017; 60: 469–76.

9. Ogura A, Konishi T, Cunningham C, et al. Lateral Node Study Consortium. Neoadjuvant (chemo)radiotherapy with total Mesorectal excision only is not sufficient to prevent lateral local recurrence in enlarged nodes: results of the multicenter lateral node study of patients with low cT3/4 rectal cancer. *J Clin Oncol*. 2019; 37: 33–43.
10. Malakorn S, Yang Y, Bednarski B, Kaur H, You N, Holliday E, et al. Who Should Get Lateral Pelvic Lymph Node Dissection After Neoadjuvant Chemoradiation? *Dis Colon Rectum* 2019; 62: 1158–66.
11. Fujita S, Akasu T, Mizusawa J, et al. Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial. *Lancet Oncol*. 2012; 13: 616-21.
12. Kusters M, Beets GL, van de Velde CJ, et al: A comparison between the treatment of low rectal cancer in Japan and the Netherlands, focusing on the patterns of local recurrence. *Ann Surg*. 2009; 249: 229-35.
13. Ogura A, Konishi T, Beets GL, et al. Lateral Nodal Features on Restaging Magnetic Resonance Imaging Associated With Lateral Local Recurrence in Low Rectal Cancer After Neoadjuvant Chemoradiotherapy or Radiotherapy. *JAMA Surg*. 2019; e192172.

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Cribb, B;Kong, J;McCormick, J;Warrier, S;Heriot, A

Title:

Lateral pelvic lymph node dissection for rectal cancer: unfinished business?

Date:

2020-07-01

Citation:

Cribb, B., Kong, J., McCormick, J., Warrier, S. & Heriot, A. (2020). Lateral pelvic lymph node dissection for rectal cancer: unfinished business?. ANZ JOURNAL OF SURGERY, 90 (7-8), pp.1228-1229. <https://doi.org/10.1111/ans.15761>.

Persistent Link:

<http://hdl.handle.net/11343/275971>